Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advances in the treatment of IDH-mutant gliomas.

Current opinion in neurology - 1 Dec 2024

Baek Chooyoung, Laurenge Alice, Touat Mehdi

Abstract excerpt

PURPOSE OF REVIEW: Isocitrate dehydrogenase (IDH) mutation is a defining molecular driver of WHO grade 2-4 astrocytomas and oligodendrogliomas. In this article, we review the recent therapeutic approaches specifically targeting IDH-mutant gliomas and summarize ongoing clinical trials in this population. RECENT FINDINGS: The IDH inhibitor vorasidenib recently demonstrated its efficacy after surgical resection in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Brain Neoplasms
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Mutation

Source

Identifiers

PMID: 39253756
DOI: 10.1097/WCO.0000000000001316

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advances in the treatment of IDH-mutant gliomas.PMID 39253756Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

Targeting IDH1/IDH2 mutations in gliomas.Semantic proximity Read ↗

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Semantic proximity Read ↗

Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.Semantic proximity Read ↗

Treatment of IDH-mutant glioma in the INDIGO eraSemantic proximity Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

IDH mutant high-grade gliomasSemantic proximity Read ↗

IDH-mutant gliomas in children and adolescents - from biology to clinical trialsSemantic proximity Read ↗

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.